Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Oral treatment with cenerimod shows promising safety and efficacy in people with mild to moderate systemic lupus erythematosus (SLE), including reduced disease activity and lower levels of immune cells ... Read more
Adding anifrolumab to standard-of-care treatment significantly reduced disease activity, corticosteroid use, and severity of skin lesions in people with moderate-to-severe systemic lupus erythematosus (SLE), according to data from a ... Read more
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Gazyva (obinutuzumab) for the treatment of adult patients with lupus nephritis, a life-threatening kidney ... Read more
Autoantibodies targeting certain regulatory RNAs — molecules that serve as the template for protein production — in the brains of lupus patients are unique to these people and involved in neuropsychiatric ... Read more
Gazyva (obinutuzumab) in combination with standard-of-care agents significantly increases the percentage of patients with proliferative lupus nephritis achieving complete or partial renal response, top-line data from a Phase 2 ... Read more
The U.S. Food and Drug Administration (FDA) has approved, under priority review, the use of Benlysta (belimumab) for the treatment of children age 5 and older with systemic lupus erythematosus (SLE). ... Read more